| Summary: | consist of diabetes and raised fasting plasma glucose, abdominal obesity, high
cholesterol and high blood pressure. Non-Alcoholic Fatty Liver Disease (NAFLD) is
considered as manifestation of the hepatal metabolic syndrome, and insulin resistance
plays a role in its pathogenesis. Strong association between insulin resistance,
elevated of free fatty acids levels and NAFLD causes the use of drugs that improve
insulin sensitivity is expected to affect the plasma free fatty acids levels and can be
use for preventing and improving NAFLD.
This study aims to determine the effect of metformin and telmisartan on
plasma free fatty acids levels in patients with metabolic syndrome and NAFLD.
This study used a one group pretest-posttest design to look for plasma free
fatty acid levels before and after the administration of metformin and telmisartan for
12 weeks. The study was conducted at the Endocrinology Clinic, Dr. Sardjito
Hospital. The study began in November 2012 until January 2013. Plasma free fatty
acid levels difference before and after treatment were statistically assessed by paired
t-test or Wilcoxon test. Differences are considered significant if P <0.05 with 95%
confidence interval.
There are 19 subjects who meet the inclusion and exclusion criteria, only 18
subjects included in the analysis. Mean plasma free fatty acids levels decreases
significantly after administration of metformin and telmisartan for 12 weeks, {p =
0.009 (80.167 to 473.253), 95% confidence interval}. This finding was in line with
the improvements on metabolic syndrome parameters including weight loss, waist
circumference and fasting blood glucose levels even though the results were not
statistically significant.
Metformin and telmisartan therapy for 12 weeks in patients with metabolic
syndrome and NAFLD can significantly reduce levels of plasma free fatty acids.
|
|---|